Pfizer/BioNTech COVID-19 Vaccine Highly Effective 6 Months After Second Dose – Pulmonology Advisor
The Pfizer/BioNTech COVID-19 vaccine is more than 91 percent effective six months after people get their second dose.
The Pfizer/BioNTech COVID-19 vaccine is more than 91 percent effective six months after people get their second dose.
Researchers assessed whether clinicians are following the updated GINA and NHLBI mild asthma guidelines, which do not recommend SABA use.
Researchers in the US assessed a 4-month tuberculosis treatment regimen of isoniazid, rifapentine, moxifloxacin, and pyrazinamide (HPMZ).
Researchers evaluated how oral corticosteroids affected wheezing severity and hospital length of stay in preschool children with acute wheeze.
Researchers examined the clinical characteristics and efficacy of inhaled corticosteroids in post COVID-19 chronic cough during the Omicron phase of the pandemic.
Viral pneumonia, a lung infection caused by a virus, is most commonly caused by influenza virus, RSV, and coronaviruses.
Researchers sought to describe factors associated with inappropriate diagnosis of community-acquired pneumonia in hospitalized patients.
Researchers identified metabolites which are unique to and shared by children with food allergy and/or asthma, using birth cohort data from inner city children.
Investigators described the clinical characteristics, management, and outcomes of pediatric egg-induced anaphylaxis.
Researchers evaluated how AIRQ compared with other asthma evaluation modalities in assessing asthma control and predicting exacerbation risk.
Researchers evaluated the reliability and accuracy of online resources describing inhaler techniques, comparing online information with product profiles.